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Abstract 
Background and Aims: Endocuff and Endocuff Vision are effective mucosal exposure devices 
for improving polyp detection during colonoscopy. AmplifEYE is a knock-off device that 
appears similar to the Endocuff devices but has received minimal clinical testing.  
 
Methods: We performed a randomized controlled clinical trial using a noninferiority design to 
compare Endocuff Vision with AmplifEYE. 
 
Results: The primary endpoint of adenomas per colonoscopy was similar in AmplifEYE at 1.63 
(2.83) versus 1.51 (2.29) with Endocuff Vision; p=0.535. The 95% lower confidence limit was 
0.88 for ratio of means, establishing noninferiority of AmplifEYE (p=0.008). There was no 
difference between the arms in mean insertion time, and mean inspection time (withdrawal time 
minus polypectomy time and time for washing and suctioning) was shorter with AmplifEYE (6.8 
minutes vs 6.9 minutes, p=0.042).  
 
Conclusions: AmplifEYE is noninferior to Endocuff Vision for adenoma detection. The decision 
of which device to use can be based on cost. Additional comparisons of AmplifEYE to Endocuff 
by other investigators are warranted.   
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Introduction 
Effective detection of precancerous lesions during colonoscopy reduces the risk of interval 
colorectal cancer1. A variety of tools are available to improve detection during colonoscopy, 
including the mucosal exposure devices, Endocuff 2-8  and Endocuff Vision 9-11. The original 
Endocuff device (Arc Medical Design, Leeds, UK) had 2 rows of fingers (Figure 1) and has been 
replaced by the Endocuff Vision, which has a single row of fingers that are 3 mm longer than 
those on the original Endocuff (Figure 1). Meta-analyses indicate that Endocuff produced an 
average 7% increase in the adenoma detection rate (ADR) 12. A head-to-head comparison of 
Endocuff to EndoRings and including the FUSE wide angle colonoscope, found that Endocuff 
was associated with faster insertion times to the cecum and better detection, indicating that is 
was a dominant mucosal exposure device from the perspective of performance13 . Recent studies 
measuring insertion and withdrawal times suggest that Endocuff Vision can provide better 
detection with less inspection time during withdrawal 10, 14. 
 
AmplifEYE is a “knock-off” device with a single row of fingers and an overall appearance very 
similar to Endocuff Vision (Figure 1). By our measurement the AmplifEYE device is 1 mm 
longer than Endocuff Vision (25 versus 24 mm), and the Endocuff Vision arms are slightly 
shorter and more acutely angulated than the AmplifEYE arms. Endocuff Vision has slots in the 
body of the device to accommodate the arms when they fold down during insertion, whereas 
there are no such slots on AmplifEYE. Otherwise, the measurements and concept of the devices 
appear very similar (Figure 1). There are few data on the effect of AmplifEYE on detection 
compared with standard colonoscopy. In one randomized trial we identified on AmplifEYE in an 
abstract form, the device produced a 94% increase in polyps per colonoscopy compared with 
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standard colonoscopy (2.09 vs 1.07, p=0.005), but showed only a trend for an increase in 
adenomas per colonoscopy (1.14 vs 0.75, p=0.083)15. Because Endocuff Vision appears 
established as effective, and AmplifEYE appears to be an alternative that should function 
similarly, we performed a randomized controlled trial to test whether performance differences 
exist between Endocuff Vision and AmplifEYE.  
 
 
Methods 
We performed a randomized controlled clinical trial comparing the Endocuff Vision (Arc 
Medical Design, Leeds, UK) with AmplifEYE (Medivators Inc, Minneapolis, Minn). Permission 
to perform the study was granted by the Institutional Review Board at Indiana University on 
April 12, 2018. The trial was registered at Clinicaltrials.gov on June 6, 2018 as NCT03560128. 
Patients were recruited for the study between April 12, 2018 and December 18, 2018. Devices 
for both arms of the study were supplied by the manufacturers. No other support was received 
from either manufacturer. Neither manufacturer played any role in the design or conduct of the 
study or reviewed the results before publication. 
 
The study was performed at 2 outpatient endoscopy units, one located at Indiana University 
Hospital and the second at a free-standing outpatient unit in Carmel, Indiana. Seven attending 
endoscopists participated in the study. 
 
Eligible patients were those aged ≥40 years presenting for screening, surveillance, or diagnostic 
colonoscopy. Patients were excluded if they had previous resection of the colon or rectum, 
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inflammatory bowel disease, a polyposis syndrome, were referred for a procedure to remove a 
specific polyp, or referred for a previous incomplete colonoscopy (failed cecal intubation). 
 
Patients were randomized to utilize the Endocuff Vision versus AmplifEYE using a computer 
generated randomization sequence. All patients provided informed consent to participate. 
Allocation was concealed using opaque envelopes until just before initiation of the procedure.  
 
The primary endpoint for the study was the number of conventional adenomas per colonoscopy 
(APC). Secondary endpoints included the adenoma detection rate (ADR), the number of sessile 
serrated polyps per colonoscopy (SSPPC), number of patients with ≥1 sessile serrated polyp 
(sessile serrated polyp detection rate or SSPDR), number of patients with ≥1 polyp (polyp 
detection rate or PDR), number of polyps per colonoscopy (PPC), insertion time to the cecum, 
overall withdrawal time (including time for washing and polypectomy), and inspection time 
(overall withdrawal time minus the time for performance of polypectomy or biopsy and suction 
and washing ). The time to insert to the cecum and the inspection time were measured by an 
assistant using a stopwatch. During insertion, the clock was stopped only when a polyp was 
detected and removed, but not for suctioning or washing. During withdrawal, the inspection time 
was measured by stopping the clock for all suctioning and washing as well as for removal of 
polyps or taking biopsies. Other secondary endpoints included the Boston Bowel Preparation 
Score (BBPS), the percentage of cases in which the device was removed to pass the sigmoid 
colon, and the cecal intubation rate. Proximal colon was defined as transverse colon and 
proximal, and distal colon was defined as splenic flexure and distal. 
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Seven attending gastroenterologists performed the colonoscopy withdrawals in the study. All 
have ADRs above the recommended threshold of 25% as measured in our quality program (data 
not shown). All are full-time lumenal clinical gastroenterologists. Median years as an attending 
in our units was 8 years. The majority (73%) of study procedures were performed by the senior 
author. Fellows assigned to assist specific physicians were allowed to perform insertion to the 
cecum, but did not perform withdrawal in patients participating in the study. The insertion time 
is presented for cases with and without fellow participation. Device removal was at the discretion 
of the attending endoscopist in all cases. 
 
Statistical analysis: Based on previous data we estimated that the Endocuff Vision will result in 
an APC of 2.3. We considered a clinically acceptable APC for the Medivators device to be 
within 20% of this value or 1.84. To demonstrate noninferiority, using a one-sided 2-sample t-
test, a coefficient of variation 1.5 for both groups a sample size of 588 patients (294 per group) 
needed to be randomized to have 80% power with a noninferiority margin of 20%. 
 
The Endocuff Vision and AmplifEYE groups were compared for differences in categorical 
variables using chi-square tests, for differences in adenoma and polyp counts using negative 
binomial models, and for differences in other continuous variables using Wilcoxon Rank Sum 
tests. A 5% significance level was used for all tests. All analyses were performed using SAS 
version 9.4 (SAS Institute Inc, Cary, NC). 
 
 
Results 
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Figure 2 shows a flow chart for patients screened, randomized, and who completed the study. 
There were 592 patients that were randomized and completed the study. Table 1 shows a 
comparison of demographic and some procedure features between the 2 study arms and 
demonstrates that there was no difference between groups in these factors.  
 
The cecum was intubated in 591 of the 592 randomized patients. The AmplifEYE device was 
removed to pass the sigmoid colon in 17 cases (6%) versus 15 (5%) with Endocuff Vision; 
p=0.687.  There were no adverse events, either perforation or significant mucosal tearing, in the 
study. 
 
On an intent to treat basis, the primary endpoint of adenomas per colonoscopy (APC) was similar 
with AmplifEYE at 1.63 (2.83) versus 1.51 (2.29) with Endocuff Vision; p=0.535. The 95% 
lower confidence limit was 0.88 for ratio of means, establishing noninferiority; p=0.008. Table 2 
shows all of the detection targets, none of which were significantly different between the study 
arms. There were also no differences between arms of the study in detection within the proximal 
or the distal colon (Supplementary Table 1). 
 
Table 3 shows the results by individual study physician. Most of the study procedures were 
performed by a single physician. One physician with a small number of cases had a higher APC 
with Endocuff Vision. 
 
The mean insertion time overall was 336 (221) seconds with AmplifEYE versus 331 (243) with 
Endocuff Vision; p=0.532. A gastroenterology fellow was involved in approximately one-quarter 
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of insertions in both arms. Considering only procedures when no fellow was involved, there was 
again no difference between study arms. Overall withdrawal times were similar and there was a 
small but statistically significant difference in inspection times among the arms. Similarly, there 
was no difference between the study arms in BBPS (Table 1).  
 
  
Discussion 
In a randomized controlled trial, we compared whether the AmplifEYE mucosal exposure 
device, which appears to be modeled on the Endocuff Vision, provides similar performance 
characteristics for detection during colonoscopy. Our results suggest that there are no major 
functional differences between the 2 devices. Thus, detection targets in the study were similar, as 
were insertion times and the percentage of cases in which the device was removed to accomplish 
sigmoid colon passage. The adjusted withdrawal time was actually slightly shorter with 
AmplifEYE than Endocuff Vision, though this was a secondary endpoint for the study. 
Considering all of the primary and secondary endpoints, it appears our study did not identify 
significant performance deficiencies in AmplifEYE.  
 
Although seven attending clinical gastroenterologists performed the study colonoscopies, the 
majority were performed by the lead author. Our approach in recent detection studies in our unit 
is to report the results by individual author13, 16, which is informative by demonstrating that 
device utility can be operator dependent13. The very high APC in both arms of this study by the 
lead author likely reflects that some surveillance patients have had previous large polyps 
resected, which are associated with a high prevalence of additional adenomas17. 
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Our results could be interpreted to suggest that colonoscopists considering the use of a mucosal 
exposure device like Endocuff Vision or AmplifEYE could make the decision based largely on 
cost. The cost of add on devices used during colonoscopy is a major issue for many practicing 
colonoscopists. Although the cost per case is low and typically around $25 per device, the profit 
margin for colonoscopy in ambulatory surgery centers and office practices in the United States is 
narrow, and the device cost reduces the facility fee profit margin significantly. From a societal 
perspective, the use of mucosal exposure devices may be cost effective based on the increased 
ADR that they provide 18, 19 . Higher ADR is associated with higher polypectomy, pathology 
costs, and with more patients returning at shorter intervals for repeat colonoscopy. However, the 
high costs of cancer care offset the increased colonoscopy costs, so that higher ADRs are cost-
effective. From the perspective of the endoscopy unit, the cost of add on mucosal exposure 
devices may be offset by improved reimbursement for polypectomy charges and increased total 
numbers of colonoscopies for surveillance over time when current postpolypectomy surveillance 
recommendations are followed 20. In addition, the savings in time from shorter average 
colonoscope insertion and withdrawal times could improve endoscopy unit efficiency, and 
potentially allow for additional procedures per working day 21. Despite these considerations, the 
obstacles created by cost indicate the need for similarly functioning devices with lower unit 
costs. 
 
Endocuff Vision and AmplifEYE, when combined with high definition colonoscopes, may 
dominate other mucosal exposure devices for increasing detection13. However, a variety of 
approaches to improving ADR are now proven effective, including education on lesion 
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appearance and withdrawal technique1, 22, double right colon segment examination23, 24, and 
patient rotation to optimize colonic distention25. Highlighting tools such as chromoendoscopy26, 
27
, narrow-band imaging (Olympus Corporation, Center Valley, Pa)28, blue-light imaging 
(Fujifilm Co, Tokyo, Japan)29, 30, linked color imaging (Fujifilm)31, 32, and artificial intelligence 
highlighting33 are also effective. Mucosal exposure devices and highlighting devices are 
potentially additive in their detection benefits. 
  
Strengths of this study include its randomized design and large size. All of the study 
endoscopists had ADRs above recommended thresholds. Because some meta-analyses have 
suggested that the main benefits of detection devices occur in low-level detectors 12, there should 
be consideration of repeating the study in a group with lower baseline ADRs. However, a recent 
study showed that even very high-level detectors have improved detection with Endocuff 13. 
Because the effects of mucosal exposure devices and other imaging features can be operator 
dependent, we recommend that other groups investigate the issue addressed by this study.  
 
In conclusion, we found that AmplifEYE, a “knock-off” device that appears very similar in 
design to Endocuff Vision, has performance features similar to Endocuff Vision. These results 
suggest that cost can be considered by colonoscopists choosing between Endocuff Vision and 
AmplifEYE. We recommend that additional groups evaluate this issue.  
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Table 1. Patient and procedure characteristics in both groups 
 AmplifEYE, n=294 Endocuff Vision, n=298 P value 
Age, years (SD) 62.1 (10) 63.2(9.7) 0.182 
Male gender, n (%) 139 (47) 128 (43) 0.29 
White, n (%) 264 (90) 268 (90) 0.767 
Indication for procedure, n (%) 
Screening 
Diagnostic 
Surveillance 
 
100 (35) 
18 (6) 
171 (59) 
 
113 (38) 
24 (8) 
160 (54) 
0.385 
Fellow participation during insertion, n (%) 71 (24) 80 (27) 0.452 
Prior abdominal surgery, n (%) 134 (46) 153 (51) 0.161 
Total procedure time, min(SD) 21.1 (7.8) 21.5 (7.6) 0.215 
Insertion time, min (SD) 
With fellow participation 
Without fellow participation 
5.6 (3.7) 
8.4 (5.2) 
4.7 (2.5) 
5.7 (4.1) 
7.5 (4.6) 
5.03 (3.6) 
0.532 
0.292 
0.390 
Overall Withdrawal time, min (SD) 14.6 (6.2) 14.9 (6.3) 0.28 
Inspection time†, min (SD) 6.8 (2.3) 6.9 (1.6) 0.042 
Boston Bowel Preparation Score 
BBPS – Right colon segment 
BBPS – Transverse colon 
BBPS – Left colon segment 
8.8 (0.7) 
2.9 (0.3) 
2.9 (0.3) 
2.9 (0.3) 
8.7 (0.9) 
2.9 (0.3) 
2.9 (0.3) 
2.9 (0.3) 
0.912 
0.452 
0.511 
0.76 
 
† Overall withdrawal time minus the time spent for washing and polypectomy (all patients) 
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Table 2. Detection targets  
 AmplifEYE, 
n=294 
Endocuff Vision, 
n=298 
2-sided 
P value 
P value for 
noninferiority† 
APC (SD) 1.63 (2.8) 1.51 (2.3) 0.535 0.008* 
ADR, n (%) 164 (56) 159 (53) 0.553 <0.001* 
SSPPC (SD) 0.21 (0.7) 0.25 (0.7) 0.552 0.38 
SSPDR, n (%) 40 (14) 46 (15) 0.527 0.314 
PPC (SD) 2.71 (3.4) 2.55 (2.9) 0.498 0.001 
PDR, n (%) 229 (78) 231 (78) 0.913 <0.001 
AAPC (SD) 0.11 (0.4) 0.10 (0.4) 0.881 0.192 
AADR, n (%) 25 (9) 23 (8) 0.726 0.124 
 
† With a margin of 20%, 1-sided test;  
* For APC, ratio of noninferiority (95% CI): 1.08 (0.88-1.33); For ADR, ratio of noninferiority (95% CI): 
1.05 (0.92-1.18) 
APC-Adenomas per colonoscopy, ADR-Adenoma detection rate, SSPPC-Sessile Serrated Adenoma/Polyps 
per colonoscopy, SSPDR-Sessile Serrated Adenoma/Polyp detection rate, PPC-Polyps per colonoscopy, 
PDR-Polyp detection rate, AAPC-Advanced adenomas per colonoscopy, AADR-Advanced adenoma 
detection rate 
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Table 3. APC by individual colonoscopists  
Doctor AmplifEye Endocuff Vision 2-sided P 
value Number of 
procedures 
Mean APC Number of 
procedures 
Mean APC  
1 6 0.17 9 1.44 0.039 
2 5 0.2 3 - 0.993 
3 7 0.29 4 1.25 0.240 
4 18 1.06 24 1.42 0.570 
5 204 1.94 226 1.61 0.193 
6 19 1.32 10 1.3 0.982 
7 35 1.0 22 0.91 0.818 
 
† APC – Adenomas per colonoscopy 
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Supplementary Table 1. Detection targets by location 
 AmplifEYE, n=294 Endocuff Vision, n=298 2-sided 
P value 
P value for 
noninferiority† 
Proximal APC (SD) 1.17 (2.3) 1.08 (1.7) 0.556 0.015 
Distal APC (SD) 0.46 (1.01) 0.43 (0.95) 0.698 0.046 
Proximal ADR, n (%) 132 (45) 134 (45) 0.987 0.007 
Distal ADR, n (%) 80 (27) 81 (27) 0.994 0.048 
Proximal SSPPC (SD) 0.15 (0.5) 0.17 (0.6) 0.571 0.406 
Distal SSPPC (SD) 0.07 (0.5) 0.08 (0.4) 0.778 0.414 
Proximal SSPDR, n 
(%) 
32 (11) 33 (11) 0.941 0.19 
Distal SSPDR, n (%) 11 (4) 17 (6) 0.261 0.7 
Proximal PPC (SD) 1.62 (2.5) 1.59 (2.1) 0.886 0.014 
Distal PPC (SD) 1.1 (1.7) 0.96 (1.4) 0.278 0.002 
Proximal PDR, n (%) 177 (60) 188 (63) 0.471 0.003 
Distal PDR, n (%) 145 (49) 145 (49) 0.872 0.002 
Proximal AAPC (SD) 0.06 (0.3) 0.07 (0.3) 0.518 0.522 
Distal AAPC (SD) 0.05 (0.3) 0.03 (0.2) 0.247 0.054 
Proximal AADR, n 
(%) 
15 (5) 17 (6) 0.746 0.373 
Distal AADR, n (%) 11 (4) 8 (3) 0.466 0.112 
†margin of 20% 
APC-Adenomas per colonoscopy, ADR-Adenoma detection rate, SSPPC-Sessile Serrated Adenoma/Polyps 
per colonoscopy, SSPDR-Sessile Serrated Adenoma/Polyp detection rate, PPC-Polyps per colonoscopy, 
PDR-Polyp detection rate, AAPC-Advanced adenomas per colonoscopy, AADR-Advanced adenoma 
detection rate 
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Figure legends 
 
Figure 1. Photograph of the original Endocuff (left), Endocuff Vision (center), and AmplifEYE 
(right). 
 
Figure 2. Flow diagram of patients through the study. 
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Acronyms list 
ADR: adenoma detection rate 
APC: adenomas per colonoscopy 
BBPS: Boston Bowel Preparation Score 
PDR: polyp detection rate 
PPC: polyps per colonoscopy 
SSPDR: sessile serrated polyp detection rate 
SSPPC: sessile serrated polyps per colonoscopy 
